Patents Examined by Sahar Javanmard
  • Patent number: 11369580
    Abstract: A nutrition formulation, which is substantially free of at least one of valine and methionine and which is capable of parenteral or enteral administration. The nutrition formulation supplies sufficient nutrients to sustain life for at least three weeks by successive administration. A composition containing the nutrition formulation can be used for treating adult cell leukemia/lymphoma.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 28, 2022
    Assignee: The University of Tokyo
    Inventors: Hiromitsu Nakauchi, Tomohiro Ishigaki, Satoshi Yamazaki, Yuki Taya
  • Patent number: 11364212
    Abstract: The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 21, 2022
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Swati Kulkarni, Bijay Kumar Padhi, Shanvas Alikunju, Rajeev Singh Raghuvanshi, Srinivas Ramchandra Sidgiddi, Anirudh Gautam
  • Patent number: 11364238
    Abstract: The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: June 21, 2022
    Assignee: PULMOKINE, INC.
    Inventor: Lawrence S. Zisman
  • Patent number: 11351179
    Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and folic acid or folate, and/or salts, metabolites, or derivatives thereof are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders or symptoms, such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 7, 2022
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 11351135
    Abstract: A method for administration of citrulline for the treatment of sickle cell disease and other complications of sickle cell disease thereof.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 7, 2022
    Assignees: VANDERBILT UNIVERSITY, THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
    Inventors: Marshall L. Summar, Frederick W. Barr, Suvankar Majumdar
  • Patent number: 11352321
    Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: June 7, 2022
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Jorge E Gomez-Galeno, Scott J. Hecker, Qun Dang, Mali Venkat Reddy, Zhili Sun, Matthew P. Grote, Thanh Huu Nguyen, Robert Huerta Lemus, Haiqing Li
  • Patent number: 11344531
    Abstract: The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: May 31, 2022
    Assignees: Servicio Andaluz de Salud, Universidad de Granada
    Inventors: Darío Acuña Castroviejo, Germaine Escames Rosa, Pablo Bueno Laraño, Alfonso Mansilla Roselló, José Antonio Ferrón Orihuela, José Jorge Hernández Magdalena, Miguel Ángel Calleja Hernández, Desirée González Callejas, Ana Comino Pardo, Carmen Olmedo Martín, Carmen Venegas Maldonado
  • Patent number: 11318142
    Abstract: The present invention is aimed at a novel composition for use as a medicament; it is also aimed at said composition for use in the treatment of depressive and anxiety syndromes. In particular, said composition is for use in the treatment of: major depression, generalized anxiety disorder, social phobia, panic disorder, mixed depression and anxiety disorder, somatoform disorder, treatment-resistant depression, obsessive-compulsive disorder. The invention also relates to a process for the preparation of said pharmaceutical composition.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: May 3, 2022
    Inventor: Milo Turri
  • Patent number: 11318110
    Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: May 3, 2022
    Assignee: Caliway Biopharmaceuticals Co., Ltd.
    Inventor: Yu-Fang Ling
  • Patent number: 11311546
    Abstract: Provided is a composition for wound healing, which includes adenine and a pharmaceutically acceptable salt thereof. Also provided is a method for enhancing wound healing in a subject in need thereof including administering to the subject the composition.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 26, 2022
    Assignee: Energenesis Biomedical Co., Ltd.
    Inventors: Han-Min Chen, Cheng-Yi Kuo, Chun-Fang Huang, Jiun-Tsai Lin
  • Patent number: 11311556
    Abstract: The invention features topical dutasteride emulsions for local delivery to the dermis of a subject suffering from hair loss, such as hair loss secondary to endocrine therapy in patients with breast cancer.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: April 26, 2022
    Assignee: Varsona Therapeutics, Inc.
    Inventors: Vinay Kumar Jindal, Manu Gujrati, Mary Angelica Oba Magsombol-Karaan
  • Patent number: 11304924
    Abstract: The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: April 19, 2022
    Assignee: Cardioxyl Pharmaceuticals, Inc.
    Inventors: Vincent Jacob Kalish, John Reardon, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
  • Patent number: 11298314
    Abstract: The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same. The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: April 12, 2022
    Assignee: AMI PHARM CO., LTD.
    Inventor: Ki Taek Lee
  • Patent number: 11266611
    Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, 1-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of 1-epinephrine, including preventing and or treating hypotension and hemostasis under surgical anesthesia.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: March 8, 2022
    Assignee: ETON PHARMACEUTICALS, INC.
    Inventor: Darren Rubin
  • Patent number: 11266652
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: March 8, 2022
    Assignee: POXEL SA
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sebastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • Patent number: 11266612
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: March 8, 2022
    Assignees: Drexel University, Rutgers, The State University of New Jersey
    Inventors: Sandhya Kortagere, Eldo V. Kuzhikandahil
  • Patent number: 11260064
    Abstract: The invention relates to pharmaceutical compositions comprising a corticosteroid and an antioxidant. The invention further relates to methods of treating, preventing, or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract comprising administering the pharmaceutical compositions comprising a corticosteroid and an antioxidant.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: March 1, 2022
    Assignee: VIROPHARMA BIOLOGICS LLC
    Inventor: Ramalingeswar Kasina
  • Patent number: 11254695
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 22, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
  • Patent number: 11253564
    Abstract: Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: February 22, 2022
    Assignee: Perfect Herbal Blends, Inc.
    Inventor: Michael Dane Backes
  • Patent number: 11241422
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 8, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David J. Lockhart, Jeff Castelli